To observe the clinical efficacy and safety of omalizumab injection combined with salmeterol ticasone inhalation powder in the treatment of patients with chest tightness variant asthma (CTVA).

Patients with CTVA were randomly divided into treatment group and control group. Patients in the control group were given salmeterol ticasone inhalation powder one puff each time, twice a day. Treatment group was given subcutaneous injection of omalizumab injection on the basis of control group, 150-600 mg per time according to symptoms, once every 4 weeks, continuous treatment for 12 weeks. Clinical efficacy, improvement of symptoms, airway resistance and lung function and safety were compared between the two groups.

A total of 10 cases dropped out during the trial, and 49 cases and 48 cases were included in the final control group and treatment group, respectively. After treatment, the total effective rates of the control group and treatment group were 79.59% (39 cases/49 cases) and 93.75% (45 cases/48 cases), respectively, with statistical significance (P<0.05). After treatment, the daytime cough scores of the control group and the treatment group were (0.51±0.17) and (0.42±0.13) score, the nighttime cough scores were (0.72±0.20) and (0.54±0.18) score, and the chest tightness scores were (0.44±0.12) and (0.37±0.09) score, forced expiratory volume in one second was (2.44±0.33) and (2.60±0.37) L, peak expiratory flow rates were (4.72±0.45) and (4.95±0.39) L·s^-1, total airway resistance measured value/predicted values were 126.34±10.77 and 121.94±9.28, central airway resistance measured value/predicted values were 86.47±6.20 and 82.16±7.33, and the differences were statistically significant (all P<0.05). The adverse drug reactions in the treatment group mainly included mild oropharyngeal edema, headache, swelling at the injection site, and epigastric pain, while those in the control group mainly included mild oropharyngeal edema, subjective palpitation, and headache. The total incidences of adverse drug reactions in the treatment group and the control group were 10.42% (5 cases/48 cases) and 8.16% (4 cases/49 cases), respectively. There was no statistically significant difference (P>0.05).

Omalizumab injection combined with salmeterol ticasone inhalation powder is more effective than monotherapy in the treatment of patients with CTVA, without increasing the incidences of adverse drug reactions.